[111In]In-DOTA-TCO-trastuzumab

N/A

Report date: 2025/11/21 17:16:22

Base Information

Drug Name[111In]In-DOTA-TCO-trastuzumab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Indium > 111In +[5]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadboud University Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical Center

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A